PUMA BIOTECHNOLOGY, INC. Form 8-K October 09, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 7, 2015

PUMA BIOTECHNOLOGY, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware (State or other jurisdiction 001-35703 (Commission 77-0683487 (IRS Employer

of incorporation)

File Number) 10880 Wilshire Boulevard, Suite 2150 **Identification No.)**

Edgar Filing: PUMA BIOTECHNOLOGY, INC. - Form 8-K

Los Angeles, California 90024

(Address of principal executive offices) (Zip Code)

(424) 248-6500

(Registrant s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

" Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) Compensatory Arrangements of Certain Officers.

On October 7, 2015, the Compensation Committee (the Compensation Committee) of the Board of Directors of Puma Biotechnology, Inc. (the Company) approved an increase in the salary of Alan H. Auerbach, the President and Chief Executive Officer of the Company, from \$630,000 to \$693,000. The increase is effective retroactively as of September 1, 2015.

In addition, on October 8, 2015, the Compensation Committee approved an increase in the salary of Charles R. Eyler, the Senior Vice President, Finance and Administration and Treasurer of the Company, from \$333,108 to \$372,600. The increase is effective retroactively as of September 1, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PUMA BIOTECHNOLOGY, INC.

Date: October 9, 2015

By: /s/ Alan H. Auerbach Alan H. Auerbach President and Chief Executive Officer